Greenleaf Trust Has $405,000 Stock Position in Sanofi (NASDAQ:SNY)

Greenleaf Trust lowered its holdings in Sanofi (NASDAQ:SNY) by 56.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,136 shares of the company’s stock after selling 10,451 shares during the quarter. Greenleaf Trust’s holdings in Sanofi were worth $405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC increased its position in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC increased its position in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA increased its position in shares of Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares during the period. Finally, CNB Bank bought a new stake in shares of Sanofi during the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $47.69 on Wednesday. The business’s fifty day moving average price is $47.58 and its two-hundred day moving average price is $48.45. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $57.82. The stock has a market capitalization of $120.64 billion, a price-to-earnings ratio of 20.21, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. As a group, analysts predict that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 58.47%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SNY. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.